Imovax Polio

Inactivated poliovirus vaccine, the active ingredient in Imovax Polio, is a vaccine presented as an injection for intramuscular and subcutaneous use. It is used to prevent poliomyelitis in infants, children, and adults by inducing immunity against poliovirus types 1, 2, and 3.

GNH USA supplies Imovax Polio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imovax Polio is an inactivated poliovirus vaccine that provides active immunization against poliovirus infection. - Poliomyelitis prevention: Provides immunity to protect against poliovirus infection and disease. - Infant and child immunization: Establishes protective antibody levels after the primary vaccination series. - Adult booster vaccination: Reinforces immunity for travelers, outbreak control, or waning protection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache: mild headache within 24 hours. - Fatigue: temporary tiredness. - Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder with muscle weakness. - Seizures: infrequent convulsive episodes. - Severe hypotension: marked drop in blood pressure. - Persistent high fever: fever lasting more than 48 hours. - Vasovagal syncope: fainting episodes post‑injection.

Imovax Polio should be administered according to national immunisation schedules and under professional supervision. - Pregnancy: safety not established; vaccinate only if clearly needed. - Breastfeeding: limited data; weigh benefits against potential risks. - Immunocompromised patients: generally safe but monitor immune response. - Known allergy: avoid if hypersensitivity to any vaccine component. - Concurrent live vaccines: may be given but follow recommended intervals. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imovax Polio may interact with other agents that affect immune response. Major Interactions (Avoid): - Immunoglobulin therapy: can reduce vaccine efficacy if given concurrently. - Live viral vaccines within 4 weeks: may interfere with immune response. Moderate Interactions (Monitor Closely): - Antipyretics: may mask post‑vaccination fever. - Immunosuppressive drugs: may diminish antibody production. - Recent blood product transfusion: possible reduced immunogenicity.